Trial Profile
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Solid tumours; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Dec 2017 Primary endpoint (Phase II: Effect of eltrombopag compared to placebo on the scheduled Day 1 pre-chemotherapy platelet counts will be evaluated across all cycles in the study) has not been met, according to the results published in the International Journal of Hematology
- 01 Dec 2017 Results published in the International Journal of Hematology
- 20 Apr 2016 Time frame for primary endpoints has been changed.